Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orforglipron in Obesity or Overweight with Osteoarthritis of the Knee
NCT07153471Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2025
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of orforglipron in obesity, osteoarthritis (OA), sponsored by Eli Lilly and Company. Started Sep 2025; status: active, not recruiting.
02
Drugs
orforglipron
03
Conditions
obesityosteoarthritis (OA)
Beyond the preview
Go deeper on NCT07153471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07153471.